Fabentech has received Marketing Authorisation in France for Ricimed, an antidote designed to treat ricin poisoning, marking ...
Oxford Drug Design has announced new in vivo results that further validate its emerging first‑in‑class oncology programme, ...
The MHRA has authorised GSK’s Nucala (mepolizumab) in the UK as an add‑on maintenance treatment for adults with uncontrolled ...
Bial has introduced a new sublingual formulation of apomorphine in the UK, offering a fresh treatment option for adults with Parkinson’s disease who experience intermittent OFF episodes that are not ...
STORM Therapeutics has entered a new collaboration with US‑based AlidaBio to accelerate the development of cancer therapies that target RNA modifications.
The inaugural Excellence in Healthcare Partnerships (EHP) Awards and Networking Evening is taking place at the Grand Connaught Rooms, London at 5pm on 5th February 2026. An evening of discussion, ...
Johnson & Johnson has submitted a Type II variation application to the European Medicines Agency for an extension of ...
Acesion Pharma has begun enrolling patients into a phase 2 clinical trial of AP31969, its novel oral SK ion channel inhibitor being developed for rhythm control in atrial fibrillation.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results